Souhaitez-vous accéder aux communiqués récents ?

These findings reinforce the importance of continuing to deepen our understanding of the underlying biology that drives both growth and resistance.

After a thorough process, management are pleased to undertake this pivotal step for GMP production of PRP for the upcoming Phase 1 FIH clinical study

Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial

An update on corporate progress and reported third quarter financial results as of March 31, 2026 (Year end June 30).

GTB-5550 is now the 3rd TriKE® to enter the clinic and an expansion into a broader solid tumor opportunity, with the Phase 1 trial likely to focus on prostate cancer patients during the dose...

Tacalyx Secures €11 Million to Advance Lead TACA-Targeting ADC Programme Toward the Clinic Berlin, Germany, April 29, 2026 (GLOBE NEWSWIRE) -- Tacalyx, a leader in the discovery and development of...

The goal is to strengthen our intellectual property and to better understand how PRP technology can overcome resistant tumors and age-related diseases.

Conventional chemo hits walls of resistance, brutal toxicity, and minimal progress. PRP changes the game.

The purpose of the study will be used as an important tool to measure the concentration of PRP and its analytes over time upon administration to patients

Kainova Therapeutics announces positive Phase I results for DT‑9081, showing strong safety, target engagement and early anti‑tumor activity.